Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction oriented QSAR modelling of EGFR inhibition.
Szántai-Kis C, Kövesdi I, Eros D, Bánhegyi P, Ullrich A, Kéri G, Orfi L. Szántai-Kis C, et al. Among authors: eros d. Curr Med Chem. 2006;13(3):277-87. doi: 10.2174/092986706775476098. Curr Med Chem. 2006. PMID: 16475937
Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.
Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Erös D, Mészáros G, Hollósy F, Hafenbradl D, Obert S, Klebl B, Kéri G, Orfi L. Székelyhidi Z, et al. Among authors: eros d. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6. doi: 10.1016/j.bmcl.2005.04.064. Bioorg Med Chem Lett. 2005. PMID: 15925511
Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.
Kéri G, Székelyhidi Z, Bánhegyi P, Varga Z, Hegymegi-Barakonyi B, Szántai-Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Erös D, Horváth Z, Greff Z, Marosfalvi J, Pató J, Szabadkai I, Szilágyi I, Szegedi Z, Varga I, Wáczek F, Orfi L. Kéri G, et al. Among authors: eros d. Assay Drug Dev Technol. 2005 Oct;3(5):543-51. doi: 10.1089/adt.2005.3.543. Assay Drug Dev Technol. 2005. PMID: 16305311 Review.
Structure -activity relationships of PDE5 inhibitors.
Eros D, Szántai-Kis C, Kiss R, Kéri G, Hegymegi-Barakonyi B, Kövesdi I, Orfi L. Eros D, et al. Curr Med Chem. 2008;15(16):1570-85. doi: 10.2174/092986708784911524. Curr Med Chem. 2008. PMID: 18673225 Review.
Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis.
Hegymegi-Barakonyi B, Székely R, Varga Z, Kiss R, Borbély G, Németh G, Bánhegyi P, Pató J, Greff Z, Horváth Z, Mészáros G, Marosfalvi J, Erōs D, Szántai-Kis C, Breza N, Garavaglia S, Perozzi S, Rizzi M, Hafenbradl D, Ko M, Av-Gay Y, Klebl BM, Orfi L, Kéri G. Hegymegi-Barakonyi B, et al. Among authors: eros d. Curr Med Chem. 2008;15(26):2760-70. doi: 10.2174/092986708786242886. Curr Med Chem. 2008. PMID: 18991635
Targeted drug combination therapy design based on driver genes.
Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I. Zsákai L, et al. Among authors: eros d. Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3. Oncotarget. 2019. PMID: 31523388 Free PMC article.
22 results